Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Q P Dou

Showing results (21-30 of 44) with videos related to

Pageof 5
Sort By:
Journal of Cellular Biochemistry|March 15, 1997
Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease familyQ P Dou, B An, K Antoku, et al.
FEBS Letters|December 9, 1996
Failure to activate interleukin 1beta-converting enzyme-like proteases and to cleave retinoblastoma protein in drug-resistant cellsB An, J R Jin, P Lin, et al.
Cancer Letters|September 29, 1998
p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cellsC L Fattman, B An, L Sussman, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 24, 1999
Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cellsQ P Dou, T F McGuire, Y Peng, et al.
Cell Death and Differentiation|January 23, 1999
Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblastsB An, R H Goldfarb, R Siman, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 1991
Inducible proteins binding to the murine thymidine kinase promoter in late G1/S phaseQ P Dou, J L Fridovich-Keil, A B Pardee
Current Cancer Drug Targets|January 21, 2011
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectivesD Chen, M Frezza, S Schmitt, et al.
Current Cancer Drug Targets|January 21, 2011
Green tea polyphenols as proteasome inhibitors: implication in chemopreventionH Yang, K Landis-Piwowar, T H Chan, et al.
Cancer Research|April 1, 1993
Cyclin E and cyclin A as candidates for the restriction point proteinQ P Dou, A H Levin, S Zhao, et al.
Oncogene|June 23, 2001
Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosisC L Fattman, S M Delach, Q P Dou, et al.
Pageof 5

Showing results (21-30 of 44) with videos related to

Sort By:
Pageof 5
Journal of Cellular Biochemistry|March 15, 1997
Fas stimulation induces RB dephosphorylation and proteolysis that is blocked by inhibitors of the ICE protease familyQ P Dou, B An, K Antoku, et al.
FEBS Letters|December 9, 1996
Failure to activate interleukin 1beta-converting enzyme-like proteases and to cleave retinoblastoma protein in drug-resistant cellsB An, J R Jin, P Lin, et al.
Cancer Letters|September 29, 1998
p53-independent dephosphorylation and cleavage of retinoblastoma protein during tamoxifen-induced apoptosis in human breast carcinoma cellsC L Fattman, B An, L Sussman, et al.
The Journal of Pharmacology and Experimental Therapeutics|April 24, 1999
Proteasome inhibition leads to significant reduction of Bcr-Abl expression and subsequent induction of apoptosis in K562 human chronic myelogenous leukemia cellsQ P Dou, T F McGuire, Y Peng, et al.
Cell Death and Differentiation|January 23, 1999
Novel dipeptidyl proteasome inhibitors overcome Bcl-2 protective function and selectively accumulate the cyclin-dependent kinase inhibitor p27 and induce apoptosis in transformed, but not normal, human fibroblastsB An, R H Goldfarb, R Siman, et al.
Proceedings of the National Academy of Sciences of the United States of America|February 15, 1991
Inducible proteins binding to the murine thymidine kinase promoter in late G1/S phaseQ P Dou, J L Fridovich-Keil, A B Pardee
Current Cancer Drug Targets|January 21, 2011
Bortezomib as the first proteasome inhibitor anticancer drug: current status and future perspectivesD Chen, M Frezza, S Schmitt, et al.
Current Cancer Drug Targets|January 21, 2011
Green tea polyphenols as proteasome inhibitors: implication in chemopreventionH Yang, K Landis-Piwowar, T H Chan, et al.
Cancer Research|April 1, 1993
Cyclin E and cyclin A as candidates for the restriction point proteinQ P Dou, A H Levin, S Zhao, et al.
Oncogene|June 23, 2001
Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosisC L Fattman, S M Delach, Q P Dou, et al.
Pageof 5